2014年9月20日（星期六）下午

Saturday Afternoon, Sept.20^th, 2014

SITC-CAHON-US CACA-CSCO Joint Symposium

Subject: Cancer Immunotherapy

Venue: 1D Meeting Room, 1st Floor, Xiamen International Conference Center 

Co-chairs:  Shu-Kui Qin (CSCO) 秦叔逵

            Bernie Fox (SITC)

             Wen-Ru Song (CAHON) 宋文儒

            Myung-Ju Ahn (US CACA)

Keynote Speech

14:30~14:50  The transformation of oncology: A strategic view of immunoscore and immunotherapy

            Bernie Fox   Society for Immunotherapy of Cancer (SITC), USA

14:50~14:55  Q&A

14:55~15:15  New developments in the combination immunotherapy of cancer

            Jon Wigginton   Society for Immunotherapy of Cancer (SITC), USA

15:15~15:20  Q&A

15:20~15:40  Genetic engineering of clinical grade T cells to target cancer and pathogens

            Laurence J.N. Cooper   MD Anderson Cancer Center, USA

15:40~15:45  Q&A

15:45~16:05  Safety and clinical activity of pembrolizumab in patients with non-small cell lung cancer, melanoma, and head and neck cancer

            Myung-Ju Ahn   Sungkyunkwan University, Samsung Medical Center, South Korea

16:05~16:10  Q&A

16:10~16:30  Cancer immunotherapy update

            Wenru Song 宋文儒   Chinese American Hematologist and Oncologist Network (CAHON), USA

16:30~16:35  Q&A

16:35~16:55  Combination of Cancer Immunotherapies

            Ke Liu 刘克  Chinese American Hematologist and Oncologist Network (CAHON), USA

16:55~17:00  Q&A

17:00~17:15  New monoclonal antibody targeting on basic fibroblast growth factor (bFGF) against melanoma, lung cancer and breast cancer in vitro and in vivo

            Meng Xu 徐萌   First Affiliated Hospital, Jinan University, China

17:15~17:20  Q&A

17:20~17:35  A novel immunotherapy approach with multiple tumor antigens activated autologous T cells in HBV related hepatocellular carcinoma 

            Yanyan Han 韩研妍   SYZ Cell Therapy Co., China

17:35~17:40  Q&A

17:40~17:55  Immunohistochemical detection of the BRAF V600E mutation in Chinese melanoma patients with monoclonal antibody VE1

            Hui Liu 刘卉   Beijing Cancer Hospital, China

17:55~18:00  Q&A